HTA Submissions

Accelerate Market Access with Confidence

Navigating the complex and ever-evolving landscape of health technology assessment (HTA) and reimbursement submissions requires precision, strategy, and deep expertise. At RTI Health Solutions, we partner with pharmaceutical and medtech companies to deliver high-impact, evidence-based submissions that meet global regulatory and payer expectations.

Whether you're preparing for the EU Joint Clinical Assessment (JCA), launching in the U.S., or seeking reimbursement in international markets, our integrated team of experts is here to guide you every step of the way.

Health Technology Assessment (HTA) Utility Measures

Not One-Size-Fits-All

Download the Guidance

image of partial globe with country outlines and flags

Comprehensive Support Across the Submission Lifecycle

We offer tailored strategic and technical services to support your product’s journey from early development through post-submission engagement:

Strategic Planning & Advisory Services
- Early advice and stakeholder engagement
- Post-submission support and payer validation
Submission Development
- Full dossier writing or targeted section development
- Integration of existing materials or creation of new components
Evidence Generation & Analysis
- Burden of illness reviews
- Systematic literature reviews (clinical, utility, economic)
- Meta-analyses (Bayesian and frequentist)
- Utility research and cost/resource estimation
- Cost-effectiveness and budget impact modeling

Global Reach, Local Expertise

Our proven track record spans major HTA markets, including:

Europe: NICE (UK), SMC, AWMSG, TLV (Sweden), NCPE (Ireland), NoMa (Norway), AMNOG (Germany), Fimea/Hila (Finland), DMC/Amgros/DMA (Denmark)
North America: CADTH, INESSS (Canada), AMCP dossiers and ICER preparation (U.S.)
Australia: PBAC

We also specialize in multicountry economic modeling, ensuring your core models are efficiently adapted to meet country-specific requirements—saving time, reducing costs, and improving consistency across submissions.

HTA Considerations for Large Language Models in Healthcare

Real-World Evidence (RWE) Is No Longer Optional for Formulary Decision-Making

Insight

Real-world evidence is now essential for formulary decisions. Learn how AMCP RWE standards align with ICER, ACIP, and HTA expectations.

Using Literature Reviews to Reveal the Benefits and Demonstrate the Value of Your Product

Webinar Content

Join our webinar to explore methodologies that enhance product development, support market access, and demonstrate value through real-world case studies.

Rethinking Health Technology Assessment: Expanding Value Beyond Health Gains and Costs

Insight

Explore how HTA is evolving to include social, ethical, and environmental considerations beyond traditional health and cost metrics.

Featured Publications

Russell J, Harris M, Sun A, White B, Brodtkorb TH, Brockbank J, Lucherini S, Vo L, Milev S. Cost-effectiveness of nivolumab + platinum doublet chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer in England. Oncol Ther. 2025 Nov 15. doi: 10.1007/s40487-025-00397-5

Gnanasakthy A, DeMuro C, Mordin M, Copley-Merriman K, Mauskopf J. The role of the patient voice in health technology assessment. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A19. doi: 10.1016/S1098-3015(10)72074-X

Purser MF, Mladsi DM, Wolowacz SE. A review of NICE technology appraisals using single-arm trials. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014. Montreal, Canada.

Jia X, Zhao Y, Carrico J, Brodtkorb T-H, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. J Dermatolog Trea. 2022 Mar;33(2):740-8. doi: 10.1080/09546634.2020.1773382